Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	Unknown
Gender:	Unknown
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Acute Myeloid Leukemia Panel by FISH

ARUP test code 3016654

FISH AML Panel	Abnormal	*	(Ref Interval: Normal)

INTERPRETIVE INFORMATION: AML Panel by FISH

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

EER AML Panel by FISH	EERUnavailable

PML-RARA Translocation by FISH

ARUP test code 2002363

PML-RARA Translocation by FISH	Abnormal	*	(Ref Interval: Normal)

H=High, L=Low, *=Abnormal, C=Critical

Test Performed: Acute Myeloid Leukemia Panel by FISH (FISHAML)
Specimen Type: Bone Marrow
Indication for Testing: Acute myeloid leukemia, in relapse

RESULT
Abnormal FISH Result

inv(3) or t(3;3) GATA2::MECOM Fusion: not detected
Deletion 5q: not detected
Monosomy 7: not detected
Deletion 7q: not detected
8q22 (RUNX1T1) Gain: not detected
t(8;21) RUNX1::RUNX1T1 Fusion: not detected
11p15 NUP98 Rearrangement: not detected
11q23 (KMT2A) Rearrangement: not detected
inv(16) or t(16;16) CBFB::MYH11 Fusion: DETECTED

INTERPRETATION
This analysis showed signal patterns consistent with:
- CBFB::MYH11 fusion due to either 16p13.1/16q22 inversion or translocation in 90/200 (45.0 percent) cells scored.

The remaining probes showed normal results.

AML with CBFB::MYH11 fusion is generally associated with a favorable prognosis.

Please correlate this result with clinical and other laboratory findings.

This analysis was performed with the AML panel probes RPN1/MECOM, D5S23/EGR1, D7Z1/D7S486, RUNX1/RUNX1T1 (Abbott Molecular), NUP98 and CBFB-MYH11 (MetaSystems), and MLL (KMT2A) (CytoCell). A total of 200 cells were scored for each probe.

Cytogenomic Nomenclature (ISCN):
nuc
ish(RPN1,MECOM)x2[200],(D5S23,EGR1)x2[200],(D7Z1,D7S486)x2[200],(RUNX1T1,RUNX1)x2[200],(NUP98x2)[200],(KMT2Ax2)[200],(MYH11,CBFB)x3(MYH11 con CBFBx2)[90/200]

This result has been reviewed and approved by [redacted]

INTERPRETIVE INFORMATION: PML/RARA Translocation by FISH

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

EER PML-RARA Translocation by FISH	EERUnavailable

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
FISH AML Panel	24-166-106098	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PML-RARA Translocation by FISH	24-166-106098	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER PML-RARA Translocation by FISH	24-166-106098	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER AML Panel by FISH	24-166-106098	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical